ENTBF - Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders

Entheon Biomedical (OTCQB:ENTBF) said the first patient was enrolled in a phase 1 trial called EBRX-101 evaluating N, N-dimethyltryptamine (DMT) for addiction disorders. In the study — which is being conducted at the Centre for Human Drug Research in Leiden, The Netherlands — a single ascending dose of intravenous DMT will be administered via continuous-controlled infusion to healthy smokers. "In our view, this is a monumental occasion, marking the start of the formal clinical stage of Entheon's development of DMT as a treatment for addiction disorders," said Entheon CEO Timothy Ko. The company expects full enrollment of its first study cohort in short order. DMT is a type of hallucinogenic tryptamine that binds to serotonin receptors. Tryptamine is type of a neurotransmitter that plays a role in sleep and mood.

For further details see:

Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders